Gossamer Bio (GOSS) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed Gossamer Bio (GOSS) over the past year, gaining 21.7% versus a loss of 95.6%. MAIA Biotechnology is the larger company by market cap ($68.5 million vs $65.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | MAIA |
|---|---|---|
| Share price | $10.72 | $1.11 |
| Market cap | $65.57M | $68.54M |
| 1-day change | -4.54% | -2.63% |
| YTD return | -95.68% | -27.45% |
| 1-year return | -95.62% | +21.71% |
| 5-year return | -98.74% | — |
| EPS (TTM) | $-42.41 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $48.47M | — |
| Revenue growth (YoY) | -57.74% | — |
| Net income (latest FY) | $-170.37M | $-22.40M |
| Operating margin | -352.23% | — |
| Net margin | -351.49% | — |
| 52-week high | $309.60 | $3.19 |
| 52-week low | $8.29 | $0.895 |
| Distance from 52-week high | -96.54% | -65.20% |
| Analyst consensus | buy | none |
| Avg. price target upside | +669.40% | +981.08% |
| Average volume | 243.40K | 524.29K |
| Shares outstanding | 6.12M | 61.75M |
| Employees | 161 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAIA has outperformed GOSS by 117.3 percentage points over the past year.
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
GOSS vs MAIA FAQ
Which is bigger, Gossamer Bio or MAIA Biotechnology?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $68.54M compared with $65.57M for Gossamer Bio (GOSS).
Which stock has performed better over the past year, GOSS or MAIA?
MAIA returned +21.71% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.